All In Biotech

Drug Trial Radar · NCT07183371

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

A Phase IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of the Malaria Vaccine Candidates R78C With Matrix-M™, and the Combination of RH5.1 and R21 With Matrix-M™, in Children Aged 5-36 Months in Burkina Faso

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institut de Recherche en Sciences de la Sante, Burkina Faso; European and Developing Countries Clinical Trials Partnership (EDCTP); European Vaccine Initiative; Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)
First posted
Sep 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 5 months, up to 36 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.

Conditions

  • Malaria,Falciparum

Interventions

  • R21Biological

    A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein

  • RH5.1Biological

    A soluble protein vaccine against the RH5 antigen

  • R78CBiological

    A soluble RIPR EGF-CyRPA fusion protein vaccine

  • Matrix-M™Biological

    A saponin-based vaccine adjuvant

  • Rabivax-SBiological

    Rabivax-S is an inactivated, freeze-dried, single-dose vaccine. The vaccine contains purified, inactivated rabies antigen produced using Vero ATCC CCL 81 cells as the cell substrate, Pitman Moore (PM3218) as the virus strain, and sucrose, glycine and HSA (Human Serum Albumin) as excipients

  • MenveoBiological

    Menveo is a tetravalent meningitis vaccine that consists of one vial of MenA powder and one vial of Men CWY solution.

  • Avaxim 80Biological

    Avaxim 80 is an inactivated, adsorbed hepatitis A vaccine. Each immunising dose contains 80 antigen units of inactivated hepatitis A virus (GBM strain).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: The primary efficacy outcome is clinical malaria, defined as the presence of axillary temperature ≥37.5°C and P. falciparum parasite density >5000 asexual forms/µL.Time frame: Clinical malaria will be assessed 6 months post final vaccination
  2. Safety: To assess the safety and reactogenicity of R78C, RH5.1 and R21 with Matrix-M™ by assessing solicited adverse events (AEs) in children living in a malaria-endemic area until 6 months after administration of the final dose of vaccine.Time frame: Day 0,1-6,28,29-34,98,99-104,126,127-132,154,155-160,182,183-188.
  3. Safety: To assess the safety and reactogenicity of R78C, RH5.1 and R21 with Matrix-M™ by assessing unsolicited adverse events (AEs) in children living in a malaria-endemic area until 6 months after administration of the final dose of vaccine.Time frame: Day 0,1-6,14,28,29-34,42,56,98,99-104,112,126,127-132,140,154,155-160,168,182,183-188,196.
  4. Safety: To assess the safety and reactogenicity of R78C, RH5.1 and R21 with Matrix-M™ by assessing serious adverse events (SAEs) in children living in a malaria-endemic area until 6 months after administration of the final dose of vaccine.Time frame: Throughout study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN)

    Nanoro, Burkina Faso

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.